Screener / SEC EDGAR /CIK 0000914475 /10-K filed Feb 11, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Neurocrine Biosciences Inc NBIX

Compare with peers Embed
Planned sales, announced before they happen

10 trading plans running, 26 Form 144 notices for $88.5M

10-Q, 10-K and Form 144
Plans running now 10 William Rastetter, Julie Cooke, Richard Pops, Gary Lyons, David Boyer, Sanjay Keswani, Eric Benevich, George Morrow, Matthew Abernethy, Stephen Sherwin
Plans adopted 37 reported since May 3, 2023 Form 144 notices 26 $88.5M the sellers expected to sell

What NBIX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 5, 2026 to May 18, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
William Rastetter
Director
Adopted 10b5-1 plan Sep 3, 2026 10-Q Nov 2, 2026
Julie Cooke
Chief Human Resource Officer
Adopted 10b5-1 plan Aug 31, 2026 10-Q Nov 2, 2026
Richard Pops
Director
Adopted 10b5-1 plan Aug 27, 2026 10-Q Nov 2, 2026
Gary Lyons
Director
Adopted 10b5-1 plan Aug 18, 2026 10-Q Nov 2, 2026
David Boyer
Chief Corporate Affairs Officer
Adopted 10b5-1 plan Aug 11, 2026 10-Q Nov 2, 2026
Sanjay Keswani
Chief Medical Officer (through Sep. 25, 2026)
Adopted 10b5-1 plan Aug 7, 2026 10-Q Nov 2, 2026
Eric Benevich
Chief Commercial Officer
Adopted 10b5-1 plan Jun 9, 2026 10-Q Jul 31, 2026
George Morrow
Director
Adopted 10b5-1 plan May 26, 2026 10-Q Jul 31, 2026
Matthew Abernethy
Chief Financial Officer
Adopted 10b5-1 plan May 22, 2026 10-Q Jul 31, 2026
Stephen Sherwin
Director
Adopted 10b5-1 plan Mar 5, 2026 10-Q May 5, 2026
Richard Pops
Director
Adopted 10b5-1 plan Feb 13, 2026 10-Q May 5, 2026
Kevin Gorman, Ph.D.
Director
Ended 10b5-1 plan Feb 4, 2026 10-Q May 5, 2025
Darin Lippoldt
Chief Legal Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
David Boyer
Chief Corporate Affairs Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Eric Benevich
Chief Commercial Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Ingrid Delaet
Chief Regulatory Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Jude Onyia
Chief Scientific Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Julie Cooke
Chief Human Resources Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Kevin Gorman
Director
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Kyle Gano
Chief Executive Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Matthew Abernethy
Chief Financial Officer
Ended 10b5-1 plan Jan 20, 2026 10-Q May 5, 2026
Leslie Norwalk
Director
Adopted 10b5-1 plan Sep 12, 2025 10-Q Oct 28, 2025
Gary Lyons
Director
Adopted 10b5-1 plan Sep 3, 2025 10-Q Oct 28, 2025
Eric Benevich
Chief Commercial Officer
Adopted 10b5-1 plan Aug 28, 2025 10-Q Oct 28, 2025
George Morrow
Director
Adopted 10b5-1 plan Aug 26, 2025 10-Q Oct 28, 2025
William Rastetter
Director
Adopted 10b5-1 plan Aug 6, 2025 10-Q Oct 28, 2025
Darin Lippoldt
Chief Legal Officer
Adopted 10b5-1 plan Jun 9, 2025 10-Q Jul 30, 2025
Matthew Abernethy
Chief Financial Officer
Adopted 10b5-1 plan May 23, 2025 10-Q Jul 30, 2025
Kyle Gano
Chief Executive Officer
Adopted 10b5-1 plan May 20, 2025 10-Q Jul 30, 2025
David W. Boyer
Chief Corporate Affairs Officer
Adopted 10b5-1 plan Dec 11, 2024 10-K Feb 10, 2025
Jude Onyia, Ph.D.
Chief Scientific Officer
Ended 10b5-1 plan Nov 18, 2024 10-K Feb 10, 2025
Stephen A. Sherwin, M.D.
Director
Adopted 10b5-1 plan Nov 7, 2024 10-K Feb 10, 2025
David Boyer
Chief Corporate Affairs Officer
Adopted 10b5-1 plan Jun 14, 2024 10-Q Aug 1, 2024
Kevin Gorman, Ph.D.
Chief Executive Officer
Adopted 10b5-1 plan Jun 14, 2024 10-Q Aug 1, 2024
William Rastetter, Ph.D.
Director
Adopted 10b5-1 plan Jun 14, 2024 10-Q Aug 1, 2024
Julie S. Cooke
Chief Human Resources Officer
Adopted 10b5-1 plan Mar 17, 2024 10-Q May 1, 2024
Kyle W. Gano
Chief Business Development & Strategy Officer
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 1, 2024
Gary A. Lyons
Director
Adopted 10b5-1 plan Feb 13, 2024 10-Q May 1, 2024
Matthew C. Abernethy
Chief Financial Officer
Adopted 10b5-1 plan Feb 13, 2024 10-Q May 1, 2024
George Morrow
(Director)
Adopted 10b5-1 plan Dec 14, 2023 10-K Feb 9, 2024
Eric Benevich
(Chief Commercial Officer)
Ended 10b5-1 plan Nov 30, 2023 10-K Feb 9, 2024
Ingrid Delaet
(Chief Regulatory Officer)
Adopted 10b5-1 plan Nov 29, 2023 10-K Feb 9, 2024
Leslie Norwalk
(Director)
Adopted 10b5-1 plan Nov 28, 2023 10-K Feb 9, 2024
Shalini Sharp
(Director)
Adopted 10b5-1 plan Nov 27, 2023 10-K Feb 9, 2024
Richard Pops
(Director)
Adopted 10b5-1 plan Nov 21, 2023 10-K Feb 9, 2024
Darin M. Lippoldt
(Chief Legal Officer)
Adopted 10b5-1 plan Aug 24, 2023 10-Q Oct 31, 2023
Kevin C. Gorman
(Chief Executive Officer)
Adopted 10b5-1 plan Aug 22, 2023 10-Q Oct 31, 2023
David W. Boyer
(Chief Corporate Affairs Officer)
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 1, 2023
William H. Rastetter
(Chair of the Board of Directors)
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 1, 2023
Show the other 41 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 10, 2026 SANJAY KESWANI
Former Affiliate
53,614 $9.0M
Nov 2, 2026 GEORGE MORROW
Director
14,700 $2.1M
Oct 30, 2026 GEORGE MORROW
Director
300 $44K
Sep 14, 2026 MATTHEW C ABERNETHY
Officer
2,311 $361K
Sep 14, 2026 DAVID WARREN BOYER
Officer
4,714 $736K
Sep 9, 2026 ERIC BENEVICH
Officer
2,154 $334K
Jul 10, 2026 INGRID DELAET
Officer
4,367 $788K
Jul 9, 2026 DARIN LIPPOLDT
Officer
10,000 $1.8M
Jul 7, 2026 INGRID DELAET
Officer
14,571 $2.5M
Jun 29, 2026 DARIN LIPPOLDT
Officer
9,800 $1.7M
Jun 26, 2026 DARIN LIPPOLDT
Officer
200 $33K
Jun 5, 2026 STEPHEN SHERWIN
Director
25,000 $4.2M
Jun 2, 2026 JULIE COOKE
Officer
36,937 $5.9M
Jun 1, 2026 JUDE ONYIA
Officer
11,000 $1.7M
May 29, 2026 INGRID DELAET
Officer
2,261 $354K
May 27, 2026 JUDE ONYIA
Officer
11,000 $1.7M
May 26, 2026 DAVID WARREN BOYER
Officer
3,888 $609K
May 19, 2026 KEVIN CHARLES GORMAN
Director
245,088 $38.5M
May 15, 2026 RICHARD F POPS
Director
15,000 $2.4M
May 12, 2026 Norwalk Leslie V
Director
6,310 $1.0M
Jan 16, 2026 KYLE GANO
Officer
36,400 $4.9M
Dec 15, 2025 Norwalk Leslie V
Director
11,250 $1.7M
Dec 8, 2025 DARIN LIPPOLDT
Officer
4,376 $681K
Dec 3, 2025 GARY A LYONS REVOCABLE LIVING U/A DTD 06/08/2012
Director
15,000 $2.3M
Nov 28, 2025 ERIC BENEVICH
Officer
5,970 $905K
Nov 25, 2025 GEORGE MORROW
Director
15,000 $2.1M
Show the other 18 notices

From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.